Is Our Investment Getting Us the Health Results We're Paying For?
This article was originally published in RPM Report
Executive Summary
Pfizer CEO Jeff Kindler sees theenvironment for pharma continuing to evolve at a fast pace. In a broad, direct speech to the leading PBM trade group he notes that pharm companiesare habving to adapt to a new world in which they do not exclusively control the information about their products. The changes will force pharm to pursue new opportunites, such as product differentiation through clinical services.
You may also be interested in...
REMS 2.0: FDA Refining New Drug Safety Tools
FDA’s new post-marketing risk management authorities are receiving much more public attention in the context of the Avandia decision…but use of the REMS is actually declining. As FDAAA turns 3, it is clear that REMS are going through some growing pains. The new tools will be refined—but they are definitely here to stay.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.